Webcast Now Available of Press Conference Discussing Landmark Surgery
Involving Harvard Bioscience's Synthetic Trachea Scaffold and "InBreath"
HOLLISTON, Mass., April 30, 2013 (GLOBE NEWSWIRE) -- An archived webcast is
now available of a press conference held earlier today that detailed the first
successful transplant of a regenerated trachea in the United States. The press
conference was held at Children's Hospital of Illinois, where the surgery took
place, and where the recipient of the implant, two-year-old Hannah Genevieve
Warren, is currently recovering.
The surgery was the world's first successful pediatric regenerated trachea
transplant using a synthetic scaffold. This was also the first regenerated
trachea transplant surgery using a scaffold manufactured by Harvard Apparatus
Regenerative Technology, Inc. (HART), the wholly owned regenerative medicine
technology subsidiary of Harvard Bioscience. The implant used in the procedure
was grown in one of HART's "InBreath" bioreactors.
Additional details about the surgery can be found in the press release
"Harvard Apparatus Regenerative Technology's 'InBreath' Scaffold and
Bioreactor Used in First U.S. Transplant of a Regenerated Trachea," released
The archived webcast of the press conference is available at the following
Further, the following link leads to an NBC news video describing the landmark
About Harvard Bioscience
Harvard Bioscience, or HBIO, is a global developer, manufacturer and marketer
of a broad range of specialized products, primarily apparatus and scientific
instruments, used to advance life science research and regenerative medicine.
HBIO sells its products to thousands of researchers in over 100 countries
primarily through its 850 page catalog (and various other specialty catalogs),
its website, through distributors, including GE Healthcare, Thermo Fisher
Scientific and VWR, and via our field sales organization. HBIO has sales and
manufacturing operations in the United States, the United Kingdom, Germany,
Sweden and Spain with additional facilities in France and Canada. For more
information, please visit www.harvardbioscience.com.
About Harvard Apparatus Regenerative Technology, Inc.
Harvard Apparatus Regenerative Technology, Inc., a wholly owned subsidiary of
Harvard Bioscience, develops and manufactures devices for use within the
emerging field of regenerative medicine. These devices include bioreactors and
synthetic scaffolds for growing tissue and organs outside the body; and
injectors for stem cell therapy.
Registration Statement of Harvard Apparatus Regenerative Technology, Inc.
A registration statement including a prospectus relating to the common stock
of Harvard Apparatus Regenerative Technology, Inc. has been filed with the SEC
but has not yet become effective. These securities may not be sold nor may
offers to buy these securities be accepted before the time the registration
statement becomes effective. This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in which such an
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
Some of the statements in this press release are "forward-looking" and are
made pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. These "forward-looking" statements include
statements relating to, among other things, activities of Harvard Bioscience
and the postponed IPO and other activities of Harvard Apparatus Regenerative
Technology. These statements involve risks and uncertainties, including among
other things, market conditions that may cause results to differ materially
from the statements set forth in this press release. The forward-looking
statements in this press release speak only as of the date of this press
release. Harvard Bioscience expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to such statements to reflect any
change in its expectations with regard thereto or any changes in the events,
conditions or circumstances on which any such statement is based.
CONTACT: David Green, President
Tom McNaughton, CFO
Chane Graziano, CEO
Tel: 508 893-8999
Fax: 508 892-6135
Harvard Bioscience, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.